iPCE125

iPCE125 is a preclinical mRNA vaccine candidate developed by Cello Therapeutics. It leverages the company's proprietary Cellular Nanoparticle (CNP) platform, which involves coating synthetic nanoparticle cores with natural cell membranes (such as those from red blood cells or cancer cells) to enhance biocompatibility and targeted delivery. This biomimetic approach is designed to protect the mRNA payload from degradation and improve its uptake by immune cells. While the specific antigenic targets and primary indications for iPCE125 have not been publicly disclosed, the platform is primarily geared toward oncology and infectious diseases.